HK Stock Market Move | CARDIOFLOW-B (02160) rose by more than 5% ANCHORMAN left atrial appendage occluder system and its delivery system obtained CE mark approval.

CARDIOFLOW-B (02160) rose over 5% again, as of the time of writing, it increased by 5.38% to 0.98 Hong Kong dollars, with a trading volume of 8.2886 million Hong Kong dollars. On the news front, CARDIOFLOW-B (02160) announced that the AnchorMan left atrial appendage closure system and its guiding system have received CE marking approval (indicating certification of products sold within the European Economic Area that comply with health, safety, and environmental standards). Both the AnchorMan left atrial appendage closure system and AnchorMan left atrial appendage guiding system have been approved by the China National Medical Products Administration. The AnchorMan left atrial appendage closure system is currently the only approved semi-closed left atrial appendage closure product in China. Furthermore, the approval of CE marking for the AnchorMan left atrial appendage closure system and the AnchorMan left atrial appendage guiding system indicates that their innovative research and development design and excellent clinical performance have reached international standards. This provides a prerequisite for entering the European structural heart disease market, as well as strong support for expanding into more international markets. It is a crucial milestone in the company's development process and global strategic layout, with the potential to further expand the company's sources of income, enhance its global comprehensive competitiveness, and win more opportunities on the international stage, benefiting more patients with structural heart disease.